Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study

Large-scale screening for atrial fibrillation (AF) requires reliable methods to identify at-risk populations. Using an experimental semi-quantitative biomarker assay, B-type natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF23) were recently identified as the most suitable biomarkers for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS medicine 2021-02, Vol.18 (2), p.e1003405-e1003405
Hauptverfasser:	Chua, Winnie, Law, Jonathan P, Cardoso, Victor R, Purmah, Yanish, Neculau, Georgiana, Jawad-Ul-Qamar, Muhammad, Russell, Kalisha, Turner, Ashley, Tull, Samantha P, Nehaj, Frantisek, Brady, Paul, Kastner, Peter, Ziegler, André, Gkoutos, Georgios V, Pavlovic, Davor, Ferro, Charles J, Kirchhof, Paulus, Fabritz, Larissa
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged Atrial fibrillation Atrial Fibrillation - blood Atrial Fibrillation - diagnosis Biological markers Biology and Life Sciences Biomarkers Biomarkers - blood Body mass index Brain natriuretic peptide Cardiac arrhythmia Cohort Studies Confidence intervals Dementia disorders Development and progression Diagnosis EKG Female Fibrillation Fibroblast Growth Factor-23 Fibroblast growth factors Fibroblast Growth Factors - blood Fibroblasts Growth factors Health aspects Heart failure Heart Failure - blood Heart Failure - diagnosis Humans Male Measurement Medicine and Health Sciences Middle Aged Natriuretic Peptide, Brain - blood Natriuretic peptides Patients Peptides Prognosis Research and Analysis Methods Risk Factors Statistical analysis Validation studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!